What is Wedbush’s Estimate for ELEV FY2029 Earnings?

Elevation Oncology, Inc. (NASDAQ:ELEV) – Stock analysts at Wedbush issued their FY2029 earnings per share estimates for Elevation Oncology in a research report issued on Friday, March 7th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of $0.07 for the year. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share.

Several other research firms have also issued reports on ELEV. William Blair restated an “outperform” rating and issued a $5.00 target price on shares of Elevation Oncology in a report on Friday, March 7th. JMP Securities reaffirmed a “market outperform” rating and issued a $7.00 price objective on shares of Elevation Oncology in a research report on Thursday, December 19th. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Elevation Oncology in a research note on Monday. Finally, Stephens reissued an “overweight” rating and set a $5.00 target price on shares of Elevation Oncology in a research note on Friday, March 7th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Elevation Oncology currently has an average rating of “Buy” and a consensus price target of $6.83.

Elevation Oncology Stock Up 5.0 %

Shares of ELEV opened at $0.49 on Monday. The company has a quick ratio of 17.77, a current ratio of 17.77 and a debt-to-equity ratio of 0.45. The business has a fifty day moving average of $0.63 and a 200 day moving average of $0.62. The company has a market cap of $29.26 million, a PE ratio of -0.60 and a beta of 1.37. Elevation Oncology has a 52-week low of $0.41 and a 52-week high of $5.83.

Elevation Oncology (NASDAQ:ELEV) last announced its earnings results on Thursday, March 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELEV. Velan Capital Investment Management LP bought a new stake in shares of Elevation Oncology in the 4th quarter valued at about $25,000. Bank of America Corp DE increased its holdings in Elevation Oncology by 42.5% during the fourth quarter. Bank of America Corp DE now owns 56,839 shares of the company’s stock valued at $32,000 after buying an additional 16,962 shares during the period. SG Americas Securities LLC raised its stake in Elevation Oncology by 33.9% in the fourth quarter. SG Americas Securities LLC now owns 61,467 shares of the company’s stock worth $35,000 after buying an additional 15,560 shares in the last quarter. Two Sigma Securities LLC purchased a new stake in Elevation Oncology during the fourth quarter worth $35,000. Finally, Virtu Financial LLC bought a new stake in Elevation Oncology during the 4th quarter valued at $36,000. 83.70% of the stock is currently owned by institutional investors.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.